Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hormone Sensitive Prostate Cancer: full-pipeline trial registry
2 of 8 indexed Hormone Sensitive Prostate Cancer trials are currently recruiting.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Hormone Sensitive Prostate Cancer: 8 US clinical trials tracked, 2 recruiting.
Hormone Sensitive Prostate Cancer is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 2 of these trials.
Enrollment posture brief
Registry condition hormone-sensitive-prostate-cancer
OPEN 2 | RECR 25% | LATE 4 | EARLY 4 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)
Hormone Sensitive Prostate Cancer lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hormone Sensitive Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hormone Sensitive Prostate Cancer is recruiting below its size-band peers.
2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hormone Sensitive Prostate Cancer research.
Pfizer accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Hormone Sensitive Prostate Cancer enrolment sits around 111 participants.
Median target enrolment is 111 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.
-
Hormone Sensitive Prostate Cancer research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer
NCT07028853
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
University of Miami
NCT06392295
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
NCT02319837
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
AstraZeneca
NCT04493853
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Alliance Foundation Trials
NCT04335682
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Xiao X. Wei, MD
NCT04126070
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Atish Choudhury, MD
NCT06463457
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
Brigham and Women's Hospital
NCT06479187
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hormone Sensitive Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hormone Sensitive Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hormone Sensitive Prostate Cancer page
8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Hormone Sensitive Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Hormone Sensitive Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hormone Sensitive Prostate Cancer condition card totals 8 registered trials; most-linked intervention Enzalutamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.